Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference

Volition (NYSE AMERICAN: VNRX) presented an ELCC 2026 abstract showing that preoperative H3K27Me3-nucleosome levels measured by Nu.Q Cancer assays stratify non-small cell lung cancer prognosis.

Rhea-AI Summary

Volition (NYSE AMERICAN: VNRX) presented an ELCC 2026 abstract showing that preoperative H3K27Me3-nucleosome levels measured by Nu.Q Cancer assays stratify non-small cell lung cancer prognosis.

High H3K27Me3 levels predicted poorer recurrence-free and overall survival; low levels indicated better outcomes and potential micro-metastatic detection, with poster data and prior studies cited.

Positive

• Poster presented at ELCC Mar 26, 2026
• Interim analysis referenced up to 832 patients in prior ELCC 2025 poster

Negative

• Findings described as interim; not yet definitive for widescale clinical adoption
• Company states it is only on the path to first clinical use, implying implementation is pending

Argus Mar 26 session

+0.89% close to close Open Argus

Details

News Market Reaction – VNRX

In the Mar 26 session, VNRX gained 0.89%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights further validation of Volition’s Nu.Q® Cancer technology, with H3K27Me3...

Analysis

This announcement highlights further validation of Volition’s Nu.Q® Cancer technology, with H3K27Me3-nucleosome levels used for prognostic stratification in non-small cell lung cancer and potential identification of micro-metastatic disease. It builds on prior references involving cohorts of up to 832 patients and multiple ELCC presentations, reinforcing a focus on risk stratification and treatment decision support. Investors may watch for progression from conference data into routine clinical use and any subsequent commercial agreements or reimbursement milestones.

Key Figures

Patient cohort size: up to 832 patients Registered resale shares: 17,968,090 shares

Patient cohort size

up to 832 patients

Interim analysis of H3K27Me3-nucleosome prognostic biomarker in NSCLC (ELCC 2025 reference)

Registered resale shares

17,968,090 shares

Common stock registered for resale on Form S-3 dated 2026-02-09

Historical Context

5 past events · Latest: Mar 25

5 events

1. Mar 25

   Cancer detection data

   24h Move

   -4.9%

   Blinded validation showing ~95% early-stage cancer detection and strong sensitivity/specificity.

2. Mar 18

   Liquid biopsy breakthrough

   24h Move

   +5.3%

   Reported >99% pure ctDNA isolation with Capture-Seq and strong blinded cohort detection.

3. Mar 06

   Vet test automation

   24h Move

   +0.7%

   First automated Nu.Q® Vet Cancer Test launch with Fujifilm Vet Systems in Japan.

4. Feb 25

   Commercial momentum update

   24h Move

   +25.6%

   Update on Capture-Seq, lung cancer reimbursement, sepsis program, and CE-marked Nu.Q® NETs.

5. Feb 10

   Distribution agreement

   24h Move

   -3.0%

   New Nu.Q® Discover distributor in Japan and discussion of ~$1B addressable market.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

liquid biopsy, non small cell lung cancer, h3k27me3-nucleosome, micro-metastatic disease, +2 more

6 terms

liquid biopsy medical

"Preoperative Nucleosome Liquid Biopsy for Prognostic Stratification in Lung Cancer"

A liquid biopsy is a laboratory test that looks for tiny pieces of tumor or disease-related material — such as DNA, proteins, or cells — circulating in blood or other body fluids, allowing detection and monitoring without a surgical tissue sample. For investors, it matters because these tests can speed diagnosis, guide treatment choices, enable easier repeat testing, and create recurring revenue streams if adopted widely, affecting a medical company's growth and regulatory risk profile.

non small cell lung cancer medical

"identify which Non Small Cell Lung Cancer patients are most likely to benefit"

A broad category of lung cancers that behave and are treated differently from the faster-spreading small cell type, encompassing several common tumor kinds such as adenocarcinoma and squamous cell carcinoma. Investors care because success or failure of diagnostics and treatments for this large patient group directly affects drug sales, clinical trial outcomes, regulatory approvals and healthcare spending — similar to how a dominant product segment drives an entire supplier market.

h3k27me3-nucleosome medical

"measuring preoperative H3K27Me3-nucleosomes using Volition's simple blood test"

A chemical tag on a histone protein—specifically three methyl groups added to the 27th amino acid of histone H3—located within the nucleosome, the basic unit that packages DNA; it acts like a molecular “sticky note” that helps turn nearby genes off. Investors care because changes in this mark are linked to cancers and other diseases and can drive demand for drugs, diagnostics, or research tools, so scientific or regulatory news about it can affect biotech and pharmaceutical companies.

micro-metastatic disease medical

"may also help identify micro-metastatic disease and support systemic treatment"

Tiny clusters of cancer cells that have broken away from a primary tumor and lodged in other parts of the body but are too small to be seen on scans or measured with standard tests. For investors this matters because micro‑metastatic disease can change a patient’s outlook, drive demand for sensitive diagnostics and longer or different drug treatments, and therefore affect the market size and value of oncology tests and therapies.

prognostic biomarker medical

""H3K27Me3-nucleosome is a strong prognostic biomarker in Non-Small Cell Lung Cancer""

A prognostic biomarker is a measurable sign—like a molecule, gene pattern or lab result—that helps predict how a disease will progress over time regardless of which treatment is used. For investors, prognostic biomarkers matter because they can clarify the likely size and urgency of a patient group, shape clinical trial design and regulatory discussions, and therefore affect how a therapy or diagnostic is valued and adopted; think of it as a weather forecast for a disease that helps companies plan and investors price risk.

circulating tumor dna medical

"Synergistic Information with Circulating Tumor DNA Molecular Profiling"

Fragments of DNA shed by cancer cells into the bloodstream that act like tiny fingerprints of a tumor; they can be detected with a blood test rather than a biopsy. Investors care because circulating tumor DNA (ctDNA) enables faster, lower-cost ways to detect disease, track treatment response, identify emerging resistance and enroll patients in trials—factors that can materially affect the commercial prospects of diagnostics and therapeutics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HENDERSON, Nev., March 26, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract at the European Lung Cancer Conference (ELCC) in Copenhagen, Denmark this week. The poster highlighted the use of its Nu.Q® Cancer assays in the management of lung cancer patients.

Poster 244P : Preoperative Nucleosome Liquid Biopsy for Prognostic Stratification in Lung Cancer With Treatment Correlation¹

Joint lead author Dr. Pei-Hsing Chen, Assistant Professor, Surgical Department, National Taiwan University Hospital, Taipei City, Taiwan, said:

"A key finding from this study was that measuring preoperative H3K27Me3-nucleosomes using Volition's simple blood test allows us to identify which Non Small Cell Lung Cancer patients are most likely to benefit from closer follow-ups or secondary cancer treatment.

"While high H3K27Me3-nucleosome levels predicted poorer recurrence-free and overall survival outcomes, low H3K27me3 levels indicated significantly better outcomes.

"Volition's Nu.Q® H3K27Me3-nucleosome levels may also help identify micro-metastatic disease and support systemic treatment decision-making in high-risk patients.

"The Nu.Q® Cancer technology supports a practical approach to empower clinicians to make more informed treatment decisions and provides valuable new monitoring capabilities throughout the patient journey."

Dr Andrew Retter, Medical Consultant, Volition, said:

"Nu.Q® Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring.

"Research conducted by our long-term collaborators in Taiwan and Lyon^1-4 consistently demonstrates that our Nu.Q® Cancer technology empowers clinicians to make more informed treatment decisions and provides valuable new monitoring capabilities throughout the patient journey.

"By enriching clinical prognostication, Nu.Q® Cancer helps identify the most appropriate treatment pathway for an individual patient, supporting efforts to improve overall survival and deliver patient-centred care.

"We are now on the path to the first use of Nu.Q® in clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives"

1. Pei-Hsing Chen et al "Nucleosome Liquid Biopsy for Prognostic Stratification in Lung Cancer With Treatment Correlation" Poster 244P ELCC 2026
2. Grolleau E, et al. Circulating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular Profiling. Biomolecules. 2023;13(8):1255. https://doi.org/10.3390/biom13081255
3. Couraud S, et al  Baseline values of circulating nucleosomes in Lung Cancer: NUCLEO-LUNG study. ELCC 2024 Poster
4. Marie Piecyk et al, "H3K27Me3-nucleosome is a strong prognostic biomarker in Non-Small Cell Lung Cancer: interim results from the analysis of up to 832 patients at baseline" Poster 395 ELCC 2025

About Volition

About Volition: Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q^® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.

View original content:https://www.prnewswire.com/news-releases/volition-announces-abstract-demonstrating-risk-stratification-in-lung-cancer-presented-at-the-european-lung-cancer-conference-302726071.html

SOURCE VolitionRx Limited

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Volition (VNRX) present at ELCC on March 26, 2026 regarding lung cancer?

They presented a poster showing preoperative H3K27Me3-nucleosome levels stratify prognosis in NSCLC patients. According to the company, Nu.Q Cancer assays predicted recurrence-free and overall survival and may help identify micro-metastatic disease to guide treatment.

How do Nu.Q Cancer H3K27Me3 levels affect prognosis for NSCLC patients in the ELCC poster?

High H3K27Me3-nucleosome levels were associated with poorer recurrence-free and overall survival outcomes. According to the company, low H3K27Me3 levels indicated significantly better outcomes and may support follow-up and treatment decisions.

Does the ELCC 2026 data mean Nu.Q assays are in routine clinical use for lung cancer now?

No, the data do not indicate routine clinical use yet; implementation is still pending. According to the company, Volition is on the path to the first clinical use but wider adoption and validation remain steps to complete.

What evidence size supports Volition's H3K27Me3 claims for lung cancer prognosis?

The materials reference interim results and prior analyses including up to 832 patients. According to the company, this body of work and related studies provide consistent findings but include interim and referenced poster data.

How might Nu.Q H3K27Me3 testing change treatment decisions for NSCLC patients (VNRX)?

The test may identify high-risk patients who could benefit from closer follow-up or systemic therapy decisions. According to the company, Nu.Q Cancer offers clinicians additional prognostic information to refine individualized treatment pathways and monitoring.